SCHEMBL241524

SCHEMBL241524

Cc1c(-c2ccccn2)nc2cc(F)cc(F)c2c1Nc1nc(N2CCOCC2)ncc1-c1cccc(NS(C)(=O)=O)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 4/20 0.54
PIK3CA P42336 11/20 0.44
PTK2 Q05397 1/20 0.40
CYP1A2 P05177 3/20 0.40
CYP3A4 P08684 3/20 0.40
LMNA P02545 2/20 0.40
TSHR P16473 2/20 0.40
RECQL P46063 1/20 0.40
CLK4 Q9HAZ1 2/20 0.39
USP2 O75604 1/20 0.39
MAPK1 P28482 1/20 0.39
HIF1A Q16665 1/20 0.39
MTOR P42345 2/20 0.38
PIK3CB P42338 3/20 0.38
PDE10A Q9Y233 1/20 0.38
PIK3CG P48736 2/20 0.37
NRP1 O14786 1/20 0.37
ALDH1A1 P00352 1/20 0.37
CYP2D6 P10635 1/20 0.37
ALOX15 P16050 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL245627 0.88 PIK3CD (0.58) PIK3CDPIK3CAPTK2CYP1A2CYP3A4
SCHEMBL243055 0.82 PIK3CD (0.56) PIK3CDPIK3CACYP1A2CYP3A4USP2
SCHEMBL244881 0.82 PIK3CD (0.58) PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL247991 0.82 PIK3CD (0.61) PIK3CDPIK3CAMTORPIK3CBPIK3CG
SCHEMBL248008 0.81 PIK3CD (0.57) PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL242110 0.81 PIK3CD (0.61) PIK3CDPIK3CACYP1A2TSHRUSP2
SCHEMBL3314799 0.80 PIK3CD (0.53) PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL248303 0.79 PIK3CD (0.59) PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL247872 0.78 PIK3CD (0.46) PIK3CDPIK3CAPTK2CYP1A2CYP3A4
SCHEMBL245630 0.78 PIK3CD (0.61) PIK3CDPIK3CAPIK3CBPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2588473-A1 NITROGEN CONTAINING HETEROCYCLIC COMPOUNDS AS PIK3 -DELTA INHIBITORS Amgen Inc. (US) 2013-05-08 EP disclosed
US-20130079342-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. 2013-03-28 US disclosed
US-20130079342-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. 2013-03-28 US disclosed
US-20130079342-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. 2013-03-28 US disclosed
WO-2012003264-A1 NITROGEN CONTAINING HETEROCYCLIC COMPOUNDS AS PIK3 -DELTA INHIBITORS AMGEN INC. (US) 2012-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130079342-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES MCL1, BCL9, MALT1 PIK3CD 25/4885PIK3CA 26/4885PTK2 411/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.